XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
10. Segment Information (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Net sales Information regarding industry segments for the three months ended September 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
206.6

 
$
334.0

 
$
4.5

 
2017
$
192.7

 
$
338.0

 
$
3.4

 
 
 
 
 
 
 
Segment net profit
2018
$
10.2

 
$
22.4

 
$
0.1

 
2017
$
5.3

 
$
30.3

 
$
0.2


Information regarding industry segments for the nine months ended September 30, 2018 and 2017 is as follows (in millions):
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
 
 
 
 
 
 
 
Segment net sales 
2018
$
622.2

 
$
1,038.8

 
$
11.6

 
2017
$
546.5

 
$
982.3

 
$
10.1

 
 
 
 
 
 
 
Segment net profit (loss)
2018
$
25.7

 
$
86.8

 
$
0.1

 
2017
$
(36.4
)
 
$
90.4

 
$
0.6



Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).
Reconciliation of segment profit to consolidated income before taxes The following reconciles total segment profit to consolidated income before taxes (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2018
 
2017
 
2018
 
2017
Total segment profit
$
32.7

 
$
35.8

 
$
112.6

 
$
54.6

Foreign currency exchange losses, net
(0.7
)
 
(3.4
)
 
(1.9
)
 
(7.7
)
Net corporate operating, interest and other expense not allocated to segments
(2.5
)
 
(2.9
)
 
(6.7
)
 
(8.5
)
Change in fair market value of equity securities
318.0

 
—

 
1,420.3

 
—

Other income (expense), net
2.6

 
1.1

 
29.6

 
13.5

Consolidated income before income taxes
$
350.1

 
$
30.6

 
$
1,553.9

 
$
51.9


Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits).